schizophrenia drug News
Most Popular schizophrenia drug Story
Lilly ignored Zyprexa safety data on weight, blood sugar
The New York Times reports that Eli Lilly initially ignored data gathered on clinical trials related to Zyprexa which showed that 16 percent of patients taking the schizophrenia drug gained more than 66 pounds. Instead, they focused on the results of a smaller group of trials that showed 30 percent of patients gaining 22 pounds. Initial data indicated that patients on Zyprexa were 3.5 times more likely to experience elevated blood sugar levels than volunteers taking a placebo. …
... Read more...Latest Headlines
- April 21, 2009
- August 27, 2008
- June 16, 2008
- January 17, 2008
- January 7, 2008
- January 3, 2008
- October 16, 2007
- July 3, 2007
- December 20, 2006
- December 17, 2006
- December 6, 2006
- May 22, 2006
- November 8, 2005
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
